Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Neurolixis Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11258
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurolixis Inc (Neurolixis) is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. The company’s pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induced dyskinesia; and NLX-101 is a drug used for the treatment of breathing difficulties in Rett’s syndrome, a genetically-encoded orphan disorder. Neurolixis therapeutic focus include pre-clinical drug discovery and early clinical development of candidates targeting unmet needs in the field of neurological and neuropsychiatric illness. The company offers treatment solutions for human central nervous system disorders such as Parkinson’s disease, Rett syndrome, depression and schizophrenia. Neurolixis is headquartered in Dana Point, California, the US.

Neurolixis Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurolixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurolixis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Neurolixis Raises US$0.01 Million In Venture Financing Round 10
Partnerships 11
Neurolixis Enters into Co-Development Agreement with Jagiellonian University Medical College 11
Licensing Agreements 12
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 12
Neurolixis Inc – Key Competitors 14
Neurolixis Inc – Key Employees 15
Neurolixis Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Nov 23, 2017: Neurolixis showcased online by “LaBiotech” 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Neurolixis Inc, Pharmaceuticals & Healthcare, Key Facts 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurolixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurolixis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurolixis Raises US$0.01 Million In Venture Financing Round 10
Neurolixis Enters into Co-Development Agreement with Jagiellonian University Medical College 11
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 12
Neurolixis Inc, Key Competitors 14
Neurolixis Inc, Key Employees 15

List of Figures
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurolixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Par Pacific Holdings Inc (PARR):石油・ガス:M&Aディール及び事業提携情報
    Summary Par Pacific Holdings Inc (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company con …
  • Hamamatsu Photonics KK (6965):企業の財務・戦略的SWOT分析
    Hamamatsu Photonics KK (6965) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • RCS MediaGroup S.p.A. (RCS):企業の財務・戦略的SWOT分析
    RCS MediaGroup S.p.A. (RCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • WPP plc:企業の戦略・SWOT・財務情報
    WPP plc - Strategy, SWOT and Corporate Finance Report Summary WPP plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • GenSight Biologics SA (SIGHT):製薬・医療:M&Aディール及び事業提携情報
    Summary GenSight Biologics SA (GenSight) is a clinical stage biotechnology company that discovers and develops novel therapies for mitochondrial and neurodegenerative diseases. The company’s product pipeline comprises GS010 and GS030 developed for the treatment of retinal degenerative diseases. It d …
  • WGL Holdings, Inc.:企業の戦略・SWOT・財務情報
    WGL Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary WGL Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析
    BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Sonivate Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sonivate Medical Inc (Sonivate Medical) is a medical device company that develops and manufactures diagnostic imaging technologies. The company offers dual-plane ultrasound probe, a finger-mounted ultrasound probe that leverages innate human hand eye coordination, which with any ultrasound s …
  • PT. Indonesia Power:企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Nuformix Plc (NFX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care an …
  • Medherant Ltd:企業の製品パイプライン分析2018
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • Eurobio Scientific SA (ALERS):企業の製品パイプライン分析
    Summary Eurobio Scientific SA (Eurobio), formerly Diaxonhit SA, a subsidiary of Hellenic Petroleum SA, is a biotechnology company that provides diagnostic products. The company provides products such as TQS, used in treatment of teanus and BJI InoPlex, used for the treatment of prosthetic infection. …
  • JSW Steel Ltd:戦略・SWOT・企業財務分析
    JSW Steel Ltd - Strategy, SWOT and Corporate Finance Report Summary JSW Steel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Earthstone Energy Inc (ESTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Earthstone Energy Inc (Earthstone Energy), formerly Basic Earth Science Systems Inc is an independent oil and gas company that offers acquisition, exploration, production and development of oil and gas properties. The company's activities include acquiring, drilling, developing and producing …
  • Restaurant Brands New Zealand Limited:企業の戦略・SWOT・財務分析
    Restaurant Brands New Zealand Limited - Strategy, SWOT and Corporate Finance Report Summary Restaurant Brands New Zealand Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • American Honda Motor Co Inc:企業の戦略的SWOT分析
    American Honda Motor Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Mapfre SA (MAP):企業の財務・戦略的SWOT分析
    Mapfre SA (MAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • The Tokyo Electric Power Company Holdings., Incorporated:企業の戦略・SWOT・財務分析
    The Tokyo Electric Power Company Holdings., Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Tokyo Electric Power Company Holdings., Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Compagnie Des Alpes Sa
    Compagnie Des Alpes Sa - Strategy, SWOT and Corporate Finance Report Summary Compagnie Des Alpes Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Marksans Pharma Ltd (MARKSANS):企業の財務・戦略的SWOT分析
    Summary Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company manufactures non-sterile liquids, ointments and powder products. It offers solid oral dosage in form of tablets, hard gelatin capsu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆